For current clinical application, we recognize that a low-dose and slow-release strategy of BMP-2 applied in bone regeneration is acceptable, even in the tumor-caused bone defects, while in the OS treatment, we still maintain a prudent stand to the employment of BMP-2. Here, BMP2 is linked to neoplasm.